EGFR and cancer: The structure of a quinazoline-based deoxynojirimycin hybrid is given in Figure 3 and in vitro EGFR and α-glucosidase inhibitory activity of compounds 2(b–e) against human cancer cell lines is shown in Table 2 [26].